Jefferies Group LLC Reiterates Buy Rating for Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Jefferies Group LLC reissued their buy rating on shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) in a report published on Thursday, August 31st. The brokerage currently has a $30.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Atara Biotherapeutics from a hold rating to a sell rating in a research report on Tuesday, August 22nd. Canaccord Genuity set a $47.00 price target on shares of Atara Biotherapeutics and gave the company a buy rating in a research report on Monday, August 7th. ValuEngine downgraded shares of Atara Biotherapeutics from a sell rating to a strong sell rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a sell rating to a hold rating in a research report on Tuesday, June 27th. Finally, William Blair restated an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $25.50.

Atara Biotherapeutics (NASDAQ:ATRA) traded up 1.29% during trading on Thursday, reaching $15.65. The company’s stock had a trading volume of 288,447 shares. The firm’s 50-day moving average is $14.69 and its 200-day moving average is $15.87. The stock’s market cap is $478.25 million. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). Equities research analysts forecast that Atara Biotherapeutics will post ($3.89) EPS for the current year.

WARNING: “Jefferies Group LLC Reiterates Buy Rating for Atara Biotherapeutics, Inc. (NASDAQ:ATRA)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/09/17/atara-biotherapeutics-inc-atra-rating-reiterated-by-jefferies-group-llc.html.

In related news, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $15.02, for a total value of $66,088.00. Following the sale, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $11,081,260.34. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Christopher Haqq sold 7,604 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $14.75, for a total transaction of $112,159.00. Following the completion of the sale, the executive vice president now directly owns 362,909 shares in the company, valued at approximately $5,352,907.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,509 shares of company stock worth $650,342. Insiders own 16.10% of the company’s stock.

Several institutional investors have recently modified their holdings of ATRA. Redmile Group LLC boosted its position in Atara Biotherapeutics by 2.4% during the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock valued at $56,186,000 after acquiring an additional 63,176 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Atara Biotherapeutics by 17.8% during the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock valued at $20,901,000 after acquiring an additional 225,367 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Atara Biotherapeutics by 15.7% during the second quarter. Neuberger Berman Group LLC now owns 967,980 shares of the biotechnology company’s stock valued at $13,552,000 after acquiring an additional 131,465 shares during the last quarter. Vanguard Group Inc. boosted its position in Atara Biotherapeutics by 1.7% during the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after acquiring an additional 13,952 shares during the last quarter. Finally, EcoR1 Capital LLC boosted its position in Atara Biotherapeutics by 101.5% during the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock valued at $8,935,000 after acquiring an additional 219,000 shares during the last quarter. 82.95% of the stock is currently owned by institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply